Monitor the March 24 earnings release for revenue, R&D progress, and cash position. Assess whether the $4M offering is sufficient to fund operations. Watch for insider share issuance details in the debt settlement, which could signal confidence or further dilution.
Price Chart
Executive Summary
Quantum BioPharma (QNTM) announced it will release its Q4 and full-year 2025 financial results on March 24, 2026. Concurrently, the company disclosed plans for a $4M non-brokered private placement of convertible debentures and warrants, and a debt settlement involving issuance of shares to creditors, including insiders. No financial results were released in this announcement.
Key Financial Metrics
Key Facts
- QNTM will release its fiscal year 2025 financial results on March 24, 2026.
- Company plans a non-brokered private placement of up to 4,000 convertible debenture units at $1,000 each, totaling up to $4 million.
- Each debenture unit includes a $1,000 secured convertible debenture (1.25% monthly interest, 24-month maturity) and 250 warrants exercisable at $5.00 per share over 5 years.
- Debentures are convertible into shares at $4.00 per share.
- Company plans a debt settlement with creditors, including insiders, by issuing shares at $4.00 per share.
- Insider participation in the debt settlement qualifies as a related-party transaction, but the company relies on exemptions from valuation and minority approval requirements.
- All amounts are in Canadian dollars; securities not registered for U.S. distribution.
Financial Impact
Up to $4 million in new debt financing with potential for significant future dilution if debentures and warrants are fully converted/exercised. Debt settlement may reduce liabilities but adds dilution risk.
Risk Factors
- Significant dilution risk if debentures and warrants are converted/exercised, especially given the company's small $13M market cap.
- Debt service obligations: 1.25% monthly interest (~15% annualized) on $4M could strain limited cash resources.
- Private placement and debt settlement may be perceived negatively by investors if viewed as dilutive or favoring insiders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.32 (−25.40%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.32 (−24.92%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.32 (−29.05%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.32 (−42.00%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.32 (−37.63%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.32 (−32.95%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.32 (−24.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers